Follow-up Patients were followed from the index date (the date of GLP-1 receptor agonist prescription) until death, loss to follow-up, or the end of the study period (December 1, 2025), whichever occurred first
It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption enhancer sodium N -(8-[2-hydroxybenzoyl] amino) caprylate, which overcomes the challenges of peptide absorption in the acidic conditions of the stomach
The situation might change soon
However, with the current research, the potential risks associated with even mild iodine excess during pregnancy warrant careful consideration
consults for Novo Nordisk and is the founder of Antag Pharmaceuticals
As exciting as all this sounds, we have a long way to go to see if this hopeful hypothesis about GLP-1 agonist medications is correct